Glass House Brands (GLAS) Change in Account Payables (2020 - 2026)
Glass House Brands' (GLAS) quarterly Change in Account Payables came in at $1.9 million in Q1 2026, up 416.01% year-on-year from $359486.6 in Q1 2025, and down 76.57% on a QoQ basis from $7.9 million in Q4 2025.
Glass House Brands (GLAS) Change in Account Payables (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 7 years of Change in Account Payables data on file, last reported at $1.9 million in Q1 2026.
- On a quarterly basis, Change in Account Payables rose 416.01% year-over-year to $1.9 million in Q1 2026; TTM through Mar 2026 was $8.3 million, a 67.56% increase from a year earlier, with the FY2025 full-year figure at $5.8 million, down 30.86% from the prior year.
- Change in Account Payables for Q1 2026 stood at $1.9 million, down from $7.9 million in the prior quarter.
- Over the last five years, Change in Account Payables for GLAS reached as high as $7.9 million in Q4 2025 and fell as low as -$5.8 million in Q3 2025.
- Historically, Change in Account Payables has averaged $1.7 million across 5 years, with a median of $2.2 million in 2023.
- On a YoY basis, Change in Account Payables climbed as much as 947.75% in 2025 and fell as far as 533.62% in 2025.
- Year by year, Change in Account Payables stood at $214000.0 in 2022, then soared by 927.93% to $2.2 million in 2023, then slumped by 142.46% to -$934000.0 in 2024, then jumped by 947.75% to $7.9 million in 2025, then tumbled by 76.57% to $1.9 million in 2026.
- Per Business Quant data, the three most recent Change in Account Payables figures were $1.9 million in Q1 2026, $7.9 million in Q4 2025, and -$5.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 62.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 30.60 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 32.70 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn | 1.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.86 Mn |
| Mar 31, 2026 | 1.86 Mn |
| Dec 31, 2025 | 7.92 Mn |
| Dec 31, 2025 | 7.92 Mn |
| Sep 30, 2025 | -5.80 Mn |
| Sep 30, 2025 | -5.80 Mn |
| Jun 30, 2025 | 4.29 Mn |
| Jun 30, 2025 | 4.29 Mn |
| Mar 31, 2025 | -587,000.00 |
| Mar 31, 2025 | -587,000.00 |
| Dec 31, 2024 | -934,000.00 |
| Dec 31, 2024 | -934,000.00 |
| Sep 30, 2024 | -916,000.00 |
| Sep 30, 2024 | -916,000.00 |
| Jun 30, 2024 | 7.37 Mn |
| Jun 30, 2024 | 7.37 Mn |
| Mar 31, 2024 | 2.90 Mn |
| Mar 31, 2024 | 2.90 Mn |
| Dec 31, 2023 | 2.20 Mn |
| Dec 31, 2023 | 2.20 Mn |